Deep vein thrombosis (DVT) and pulmonary embolism (PE) cannot be diagnosed solely on a clinical basis owing to the lack of sensitivity and specificity of clinical signs and symptoms. Phlebography and pulmonary angiography are invasive and resource-demanding imaging modalities. Because the prevalence of DVT and PE is relatively low (typically 20% or less) among clinically suspected individuals, submitting all of them to imaging would not be cost-effective. Therefore, non-invasive diagnostic algorithms have been developed that include clinical probability assessment and D-dimer measurement. These initial steps allow the selection of patients who require non-invasive imaging: compression ultrasonography in cases of suspected DVT and multidetector computed tomography (CT) angiography in cases of suspected PE. This review gives a critical appraisal of the sequential steps of the diagnostic work-up in suspected DVT or PE.
Introduction
Pulmonary embolism (PE), the source of which is predominantly located in a thrombosis of the deep veins of the legs (DVT), is the third cause of mortality by cardiovascular disease following coronary artery disease and stroke. In addition, late sequels of DVT may produce disabling leg symptoms in a substantial proportion of patients, 1 including venous ulcers in a minority, resulting in a considerable economic burden. Finally, chronic thromboembolic pulmonary hypertension may develop as a late complication of PE in a small subset of patients.
During the past two decades, the approach to diagnosing DVT and PE has changed considerably. First, it has been accepted that these two conditions are different manifestations of a single entity that was called venous thromboembolism (VTE). Second, novel non-invasive diagnostic tools such as venous compression ultrasonography (CUS), fibrin D-dimer (DD) measurement, and multidetector CT angiography have become available, which have drastically reduced the need for invasive tools such as phlebography and pulmonary angiography. Third, the index of suspicion has progressively increased, which results in 80% or even more of patients with suspected VTE and referred to a diagnostic center not having the disease. Fourth, efficient, mainly noninvasive strategies have been validated in large-scale outcome studies, and attention has been paid to their costs. 2 The initial diagnostic step: clinical probability assessment Clinical probability assessment aims to: (i) identify the patients (probably those with a high and intermediate clinical probability) who require anticoagulant treatment while awaiting the results of diagnostic tests and (ii) select the patients (those with a non-high clinical probability) in whom the diagnosis of VTE can be ruled out on the basis of a negative DD test result (see below) ( Figure 1 ). VTE cannot be diagnosed on a sole clinical basis owing to the lack of sensitivity and specificity of isolated clinical signs and symptoms. 3 Indeed, clinical symptoms, signs and abnormalities of blood gases, chest radiograph, and electrocardiogram have a low predictive value for suspected DVT or PE when considered singly. Nevertheless, clinicians can combine these findings effectively either implicitly or by prediction rules or scores in order to classify patients according to their probability of having the disease, the so-called prior clinical probability. For suspected DVT, the Wells' score ( Table 1) has gained wide acceptance. 4 In patients with a low clinical probability, the prevalence of DVT is less than 5%, while it is about 15% or 70% in patients with intermediate or high clinical probability, respectively. It is easy to compute and well validated. Its only disadvantage consists of the presence of one subjective though meaningful item (i.e. the presence of an alternative diagnosis that is at least as likely as that of DVT, an item that carries a major weight in the score).
For suspected PE, two scores have been proposed (the Wells' score 5 and the Geneva score 6 ) and externally validated 7 that are as, but not more, accurate than implicit judgment. [8] [9] [10] Nevertheless, in a study of 110 patients who received duplicate assessments, Rodger et al. showed that inter-observer reliability was higher when using an explicit clinical model (kappa = 0.62 vs 0.33 for implicit evaluation). 11 In addition, explicit clinical models or scores are useful educational tools. Nevertheless, many clinicians are reluctant to use scores and prefer using clinical intuition for determining pretest risk for DVT/PE to determine whether further imaging is needed. Implicit or explicit, all these means of assessing the clinical likelihood of PE allow a fairly accurate classification of patients into three categories corresponding to a prevalence of the disease of 5-10% (low clinical probability), 20 Geneva score 6 requires arterial blood gas values while breathing room air, a variable which was not available in 15% of the patients in the external validation sample. 7 The Wells' score (Table 1) includes the clinician's judgment of whether an alternative diagnosis is more likely than that of PE. 5 That criterion carries a major weight in this score and can obviously not be standardized, even though it appears quite meaningful, as evidenced by the fact that allowing the clinician to override the totally objective Geneva score provides a statistically significant additional, albeit small, gain in performance. 7 To obviate the logistical and standardization problems of the two above-mentioned scores, the Geneva group derived a new prediction rule from a large multicenter cohort of patients admitted to the emergency ward for clinically suspected PE. 12 The rule is entirely based on clinical variables and is independent from physicians' implicit judgment (Table 1) , which might facilitate its use by non-MD health professionals. In an external validation set of the new score, the prevalence of PE was 8% in the low probability category (0-3 points), 28% in the intermediate (4-10 points), and 74% in the high probability group (≥ 11 points). 12 Although the clinical data in the validation sample were collected prospectively, this new score, the so-called Revised Geneva Score, was calculated retrospectively. To be considered fully validated, it needed to be used prospectively in a formal outcome study with patient follow-up, which was realized in two independent cohorts of 300 13 and 1819 14 patients with suspected PE. The new score exhibited performances that were similar to those obtained with the Wells' rule.
In two recent outcome studies, the Wells' score for PE has been used with a single cut-off of 4 points instead of two cut-offs. 15, 16 This results in a classification of patients into two clinical probability categories (PE unlikely or likely) instead of the traditional three levels of probability (low, intermediate or high). This would theoretically allow using a less sensitive DD assay in a higher proportion of patients than when using the three-level probability scheme but is less close to implicit clinical judgment. Nevertheless, the dichotomized score is also valid for discriminating between patients at low and higher clinical probability of PE. Simplifications of both the Wells' rule and the revised Geneva score, in which all items carry the same weight, have also been proposed and have undergone external validation. [17] [18] [19] Recently, we performed a systematic review and a metaanalysis of the performance of all available clinical prediction rules for suspected PE. 20 The conclusion was that these rules have a similar accuracy but that they are not totally equivalent and that the choice among the various prediction rules and classification schemes must be guided by the local prevalence of PE, the type of patients considered (outpatients or inpatients) and the type of DD assay applied. When using a highly sensitive DD assay, a three-level classification scheme should be preferred because it mimics more closely clinicians' empirical reasoning and potentially rules out VTE in a higher proportion of patients. Wells' score with two levels of probability (VTE likely or unlikely) should be used in combination with a less sensitive DD assay, as those assays are not safe for ruling out VTE in the 40% of patients in the intermediate clinical probability category, and the VTE unlikely category includes a higher proportion of patients than the low probability class. The performance of Wells' score for PE is sensitive to the overall prevalence of PE in suspected patients: in series where the prevalence of PE was higher than 20%, the prevalence of PE in the low and intermediate probability categories was significantly higher (16%, pooled average) than in series with a lower prevalence of the disease (3.4%). This is not problematic when using a highly sensitive DD assay, but might be a problem with less sensitive assays. We therefore advise using the revised Geneva score in populations with a prevalence of PE above 20% since that rule has been derived and validated in such patients. Finally, the Wells' score for PE (two-or three-level) is the only validated score in inpatients.
The second diagnostic step: fibrin DD measurement in patients with non-high clinical probability of VTE
Fibrin DD is a degradation product of cross-linked fibrin and its blood concentration is increased in patients with acute VTE. When assayed by a quantitative ELISA or by some automated turbidimetric assays, DD has been shown to be highly sensitive (more than 95%) in acute DVT or PE, usually with a cut-off value of 500 µg/l. Hence, a DD level below this value reasonably rules out acute VTE, at least in patients with low or intermediate clinical probability, as recently reviewed extensively. 21 Data from two large-scale recent multicenter management studies definitively establish the safety of two DD assays. The VIDAS ® D-Dimer Exclusion™ test, an ELISA assay, has now been used in 5060 patients with suspected PE. 14, 16, [22] [23] [24] [25] The disease was ruled out by a negative result in 1754 (34%) patients who had a non-high clinical probability or were classified as 'PE unlikely' in the Dutch series. 16 The 3-month thromboembolic risk was only 0.1% (95% CI, 0 to 0.4), a low figure that was fully confirmed in a subsequent meta-analysis. 26 The Tinaquant ® test, an immunoturbimetric assay, has also been validated in three outcome studies that included 2071 patients. 16, 27, 28 The result was negative, ruling out PE in 857 (41%) patients who had either a low clinical probability of PE or were classified as 'PE unlikely' according to the dichotomized Wells' rule. 16 The 3-month thromboembolic risk was 0.6% (95% CI, 0.2 to 1.4). Finally, the SimpliRed ® assay is also well validated 21, 29, 30 but inter-observer variability may be a problem. 30 Patients with a high clinical probability should not be tested for DD because a concentration below the diagnostic cut-off is rare in this category of patients; moreover, the post-test probability of PE remains above 3% despite a negative result, which is the usual threshold above which PE is considered not to have been adequately ruled out.
Whereas DD rules out VTE in about one-third of outpatients clinically suspected of having the disease, its utility is definitely less in patients who are hospitalized for another reason and in whom the suspicion is raised during a hospital stay. Likewise, elderly patients benefit less from this test. 21 This is due to the lack of specificity of the test: although DD is very specific for fibrin, the specificity of fibrin for VTE is poor because fibrin is produced in a wide variety of conditions such as cancer, inflammation, infection or necrosis -all conditions that are more likely to be present in older, hospitalized patients.
As another consequence of this low specificity of the test, a DD concentration above 500 µg/l has a poor positive predictive value for VTE, and cannot reliably rule in the disease.
Nevertheless, Bosson et al. 31 suggested in a retrospective analysis of a large patient sample that a DD level above 2000 µg/l was predictive of the presence of PE, independently of the clinical score, with an odds ratio of 6.9. These authors admit, however, that this result requires clinical validation in a prospective study, especially because the PE prevalence in their series was high: 27%, 58% and 85% in the low, intermediate, and high clinical probability categories, respectively.
The reference imaging modality for suspected DVT: compression ultrasonography (CUS)
CUS has largely replaced venography to diagnose DVT. However, its accuracy for distal (below the knee) DVT has been questioned. More importantly, the need for diagnosing isolated distal DVT is still debated. 32 At present, three options are used in clinical practice. Some groups only look at proximal (above the knee) veins and repeat the exam 1 week later in patients with a negative initial exam in order to detect clinically relevant distal thrombi that would have progressed towards the proximal vessels. Though theoretically attractive, this so-called repeat CUS procedure has a very low yield (around 1-2% positive results) and is resource demanding. Another approach is to look at proximal and distal veins in a single exam, the so-called complete venous ultrasound, which was recently shown in a meta-analysis to be associated with a low 3-month VTE rate. 33 However, this approach implies treating a large number of patients with isolated distal DVT, which is not fully supported by the evidence available and may put these patients needlessly at risk of bleeding. 32 A third approach consists of performing a single proximal CUS and to rule out DVT if negative in patients with a low or intermediate clinical probability, while patients with a high clinical probability and a negative proximal CUS would qualify for additional imaging (distal veins US imaging, venography) or serial surveillance (Figure 1) . This approach appears to be associated with a 3-month VTE risk that is very similar to that of complete CUS (28), with 30-50% fewer patients given anticoagulant treatment. Admittedly, this approach has been validated in a single series of 474 patients 34 at a time when the ultrasound equipment was far less sophisticated than today.
The 8th American College of Chest Physicians (ACCP) consensus recommendations 35 do not distinguish between proximal and isolated distal DVT nor between symptomatic and asymptomatic events and recommend the same anticoagulant treatment for all these events.
The reference imaging modality for suspected PE: multidetector CT angiography (MDCTA)
During the past few years, CTA has largely replaced ventilation-perfusion lung scintigraphy as the main imaging modality in suspected PE. The rapid acquisition of highcontrast images by CTA allows an adequate visualization of the pulmonary arteries up to at least the segmental level. 36 It was immediately recognized that sensitivity of CTA was higher in central pulmonary emboli than in segmental and subsegmental arteries but the finally reported sensitivity of the single-detector technique was only 70% -a figure reported several years ago by Perrier et al. (37) , and confirmed by a Dutch group 38 -precluding its use as a single diagnostic test. Its implementation in a sequential approach (to replace ventilation/perfusion lung scanning) has been studied in two large management studies. 8, 24 In these studies, the requirement for pulmonary angiography was less than 2%, and the 3-month thromboembolic risk was below 2%, but the work-up included lower limbs venous CUS to minimize the false-negative rate due to the low sensitivity of single-detector CTA. Indeed, in the ESSEP study, 8 55 (16%) of the 349 patients finally diagnosed with PE had a DVT despite a negative helical CT scan. The safety of the combination of single-detector CTA and CUS to rule out PE was further substantiated by a large-scale Canadian study that resulted in a 0.5% 3-month thromboembolic risk among the subgroup of 409 patients who had a negative CTA and no proximal DVT on CUS. 39 MDCTA 40 allows both a thinner collimation (1-2 mm slice thickness) and a better definition without increasing image acquisition time, and is therefore potentially more sensitive than single-detector machines. This development has raised the possibility that PE might be safely ruled out without the use of lower-limb venous ultrasonography, at least in patients without a high probability of PE -a change in strategy that could save both money and other resources. If that were true, the diagnosis of DVT in a patient with clinically suspected PE and negative findings on multidetector CTA should be uncommon, and the 3-month risk of thromboembolism in patients with a negative MDCTA scan should be low. That hypothesis was confirmed in a prospective, multicenter Swiss-French study 25 of patients admitted to the emergency department for clinically suspected PE. In this study, the proportion of patients with proximal DVT despite negative findings on multidetector CTA was very low (0.9%; 95% CI, 0.3 to 2.7). Therefore, the improvement of the overall detection rate of PE by CUS was marginal in this series, and the 3-month thromboembolic risk in patients left untreated if PE had been ruled out on the sole basis of a negative MDCTA would have been 1.5% (95% CI, 0.9 to 2.7), similar to that of pulmonary angiography 38 and other recent outcome studies. 8, 24, 29, 41 A strong support for the safety of using MDCTA as a single imaging modality arises from the CHRISTOPHER study. 16 In that series, patients with an elevated DD level or in whom PE was considered likely according to the dichotomized Wells' rule (n = 1436) underwent a CTA (multidetector CTA, 88% of the patients). The 3-month thromboembolic risk in patients not treated based on a negative CTA was 1.3% (95% CI, 0.7 to 2.0). Moreover, in the study by Ghanima et al., 42 432 consecutive outpatients clinically suspected of PE who were sequentially submitted to clinical assessment, DD measurement and MDCTA, a definitive diagnosis was reached in 96.5% of patients with a 3-month thromboembolic risk of 0.6% (95% CI, 0 to 2.2%). Collectively, those series support the safety of ruling out PE by DD measurement and multidetector CTA in non-high clinical probability patients without resorting to lower-limb CUS. The final proof was given by a multicenter, randomized, non-inferiority study that compared the strategies with and without CUS (see next section). 14 Overall, the meta-analysis by Moores et al. 43 that compiled 23 studies with 4657 patients with a negative CTA (mainly single-detector) who did not receive anticoagulation showed a 3-month rate of subsequent VTE of 1.4% (95% CI, 1.1 to 1.8) and a 3-month rate of fatal PE of 0.51 (95% CI, 0.33 to 0.76).
A Canadian randomized trial compared a V/Q scan and a multidetector CTA-based strategy for investigating suspected PE (mostly multidetector CTA). 14 Very few patients developed VTE during follow-up and there was no outcome difference between the CTA and the V/Q-based strategy.
As reviewed by Stein et al., 44 the increasing use of CTA may result in an increased incidence of radiation-related cancer in the not-too-distant future. Dangers of radiation require that protocols for CT angiography be optimized. In addition, the use of combined CT pulmonary angiography and CT venography should be questioned as it was found in PIOPED II that no patient with PE or DVT would have been undiagnosed if imaging of the pelvic veins had not been done and proximal lower limb DVT can be diagnosed by compression ultrasonography. Moreover, it has also been shown that CT venography and compression ultrasonography are diagnostically equivalent for diagnosing proximal DVT of the lower limbs. The radiation risk is particularly important in pregnant women in whom the respective advantages of CT angiography and ventilation/perfusion or perfusion-only lung scintigraphy are still debated.
What place for MR angiography and conventional pulmonary angiography in contemporary diagnostic work-up of suspected PE?
Because it is devoid of irradiation, magnetic resonance (MR) imaging is a potential candidate for diagnosing PE. Recently, the accuracy of gadolinium-enhanced magnetic resonance pulmonary angiography (MRA) and magnetic resonance venography (MRV) for diagnosing PE has been studied in a prospective, multicenter accuracy study on 371 adults with diagnosed or excluded PE from seven North American hospitals. 45 The reference standard diagnosis was made by using various tests, including computed tomographic angiography and venography, ventilation-perfusion lung scan, venous ultrasonography, DD assay, and clinical assessment. MRA, averaged across centers, was technically inadequate in 25% of patients (92 of 371). Of note, the proportion of technically inadequate images ranged from 11% to 52% across centers. Including patients with technically inadequate images, MRA identified 57% (59 of 104) of those with PE. Technically adequate MRA had a sensitivity of 78% and a specificity of 99%. Technically adequate MRA and MRV had a sensitivity of 92% and a specificity of 96%, but 52% of patients (194 of 370) had technically inadequate results. Therefore, MRA should be considered only in centers with adequate experience of the technique and only in patients for whom standard tests are contraindicated, which will limit its use to a small minority of patients at the present stage.
Conventional pulmonary angiography remains the gold standard for PE diagnosis, even though it is no longer used on a routine basis. Because of its invasive character, it should probably be restricted to patients in whom a clinically likely diagnosis could not be confirmed by other means or in those patients in whom endovascular treatment of PE is being considered.
Any place for venous compression ultrasound for diagnosing PE?
Since ultrasonography is not devoid of costs, is laborintensive and because not all centers have access to the technique, forfeiting ultrasonography would possibly reduce costs. Based on the results of the last study by the Swiss-French consortium 25 and supported by the results of the CHRISTOPHER study, 16 a randomized trial addressed this question comparing two strategies based on clinical assessment, DD and multidetector CT, with or without CUS. The prevalence of PE was 21% in both study arms. In the per-protocol analysis, the 3-month thromboembolic risk was 0.3% (95% CI, 0.1 to 1.1) in the DD-US-CT arm and 0.3% (95% CI, 0.1 to 1.2) in the arm without US, a nonsignificant difference (0.0; 95% CI, -0.9 to 0.8). Results were similar in the intention-to-diagnose analysis. In the DD-US-CT arm, ultrasonography showed a DVT, hence allowing foregoing MSCT, in 9% of patients. The mean cost per patient was significantly higher in the DD-US-CT strategy. 14 As an additional piece to this issue, Elias et al. 46 suggested that early complete (not just proximal) US examination of the lower limb veins was safe and resulted in a substantial reduction of CTA: 101 among 274 outpatients (37%) clinically suspected of PE had a DVT demonstrated by US (65 proximal, 36 distal). However, the specificity of complete US for PE (84%) was lower than that of proximal US, raising the concern of a high number of false positives and patients anticoagulated unnecessarily.
In addition, a secondary analysis of the ESSEP study 8 showed that the 3-month risk of thromboembolic recurrence or death was 6.5% in patients with PE and a CUS-detectable DVT, compared to 2.7% in those patients with PE but without DVT. 47 Admittedly, the difference was not statistically significant (p = 0.15), but a beta error cannot be excluded. On the other hand, it rather supports the hypothesis that underlying DVT might negatively influence the prognosis of patients with established PE, as shown in the prognostic score developed 48 and externally validated 49 a few years ago.
The incidence of upper extremity DVT (UEDVT) is growing, but symptomatic PE has been reported in only 9% of patients with catheter-related UEDVT 50 and in 8% of those with idiopathic UEDVT, 51 compared with 29% and 31%, respectively, in patients with lower extremity DVT. Therefore, screening for UEDVT in patients with clinically suspected PE is unlikely to be very successful and should probably be restricted to patients with clinical signs of UEDVT in whom the US diagnosis could be established with certainty, which is by far not always the case. 52
Does age have an influence on the diagnostic modalities of PE?
PE diagnosis in elderly patients is a major issue, not only because the prevalence of the disease increases with age but also because diagnosis may be more difficult due to cardiopulmonary comorbidities that are associated with ageing and can mimic the clinical presentation of PE. Sohne et al. 53 retrospectively analyzed data from two prospective studies of consecutive in-and outpatients clinically suspected of PE by categorizing them into three age groups (< 65, 65-75, > 75 years). They concluded that the proportion of patients > 75 years of age with a non-high clinical probability and a normal DD level was only 14%, whereas it was 22% and 41% in patients aged 65-75 and < 65 years, respectively. In a secondary analysis of the ESSEP study, 8 Couturaud et al. 54 studied the effect of age on the performance of a diagnostic strategy based on clinical probability, CTA and venous CUS. They found that the distribution of inconclusive CTA or CUS examinations was not different among the three tertiles of age studied (< 54, 54-73, > 73). Finally, more elderly patients had a positive result of both CTA and CUS and could have been diagnosed by CUS only. In a comprehensive review, Righini et al. 55 studied the influence of age on all commonly used diagnostic tests and strategies for suspected PE. Briefly, they concluded that age reduces the clinical usefulness of DD measurement and ventilation-perfusion lung scintigraphy. DD allows PE to be ruled out in only 5% of patients aged 80 or more, compared with 60% in those younger than 40 years old. Similarly, the proportion of inconclusive ventilationperfusion lung scans is almost twice as high (58%) in patients aged more than 70 years compared with those who are less than 40 (32%). In contrast, age did not change the diagnostic accuracy of clinical probability assessment (both implicit or explicit), nor appears to influence the diagnostic performance of venous compression US and MDCTA.
The value of individual tests for diagnosing PE
In an elegant systematic review, Roy et al. 56 assessed the likelihood ratios of diagnostic tests for PE and determined their clinical application according to the pretest clinical probability. Positive likelihood ratios for diagnostic tests were: high probability ventilation-perfusion lung scan 18.3 (95% CI, 10.3 to 32.5), CTA 24.1 (12.4 to 46.7), and ultrasonography of leg veins 16.2 (5.6 to 46.7). In patients with a moderate or high pretest probability, these findings are associated with a greater than 85% post-test probability of PE. Negative likelihood ratios were: normal or near normal appearance on lung scan 0.05 (0.03 to 0.10), a negative result on single-detector CTA along with a negative result on ultrasonography 0.04 (0.03 to 0.06), and a DD concentration < 500 µg/l measured by quantitative enzyme-linked immunosorbent assay 0.08 (0.04 to 0.18). In patients with a low or moderate pretest probability, these findings were associated with a post-test probability of PE below 5%. Single-detector CTA alone, a low probability ventilation-perfusion lung scan, MRA, a quantitative latex DD test, and haemagglutination DD had fewer low negative likelihood ratios and could therefore only exclude PE in patients with a low pretest probability. Roy et al. 57 concluded that the accuracy of tests for suspected PE varies greatly, but that it is possible to estimate the range of pretest probabilities over which each test or strategy can confirm or rule out PE. Based on all these considerations, a very simple diagnostic algorithm can now be proposed for suspected VTE (Figure 2 ).
Conclusions
Diagnosing VTE depends upon several, mainly non-invasive diagnostic tools that must be used sequentially. Using validated diagnostic algorithms is associated with a definitely lower risk of complications, according to Roy et al., 57 and should therefore be implemented in all institutions depending upon local availability and expertise, and taking into account the issue of costs. With the development of potentially more sensitive diagnostic tests such as multidetector CTA, and possibly MR pulmonary angiography (even though preliminary results suggested a low sensitivity of 71% 58 ), or calf vein ultrasonography, clinicians will face the risk of over-diagnosis, and hence overtreatment, with its associated iatrogenic risk. Therefore, the true issue in the near future may no longer be just to detect clots but rather to identify patients who must really be treated with anticoagulant drugs, which may turn out to be less easy.
